Short answer
Mineralys Therapeutics, Inc. (MLYS) filed its Q3 2026 10-Q quarterly report on Nov 4, 2026 for the quarter ended Sep 30, 2026.
Q3 2026 key financials · XBRL
- Net income
- −$57M
- −55.2% YoY · +76.2% QoQ
- EPS (diluted)
- −$0.60
- −20.0% YoY · +79.2% QoQ
Source: XBRL data from the Mineralys Therapeutics, Inc. (MLYS) Q3 2026 10-Q on SEC EDGAR. USD.
Mineralys Therapeutics, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged YoY, no product sales before potential lorundrostat approval
- Net loss $57.3M vs $36.9M YoY, R&D $22.7M vs $31.5M and G&A $37.4M vs $9.7M
- Cash, equivalents and investments $624.7M at September 30, 2026, operating cash use $115.1M
- Capital deployment: $200.0M Tanabe payment, $100.0M Tranche A borrowing, $143.6M equity proceeds
- Outlook: cash expected to fund operations through commercial launch for at least twelve months, PDUFA date December 22, 2026
Risk Factors
- New debt-servicing risk triggered by June 2026 Loan Agreement, which matures in 2031
- Secured-collateral risk: lender foreclosure could include substantially all assets and intellectual property
- Covenant risk: minimum liquidity and future net product revenue tests could accelerate repayment upon breach
- Tariff risk: lorundrostat imports may face tariffs as high as 100% of imported value
- Financing risk: inflation and trade-policy uncertainty could make additional capital more costly or dilutive
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Mineralys Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.